Corebridge Financial Inc. Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Corebridge Financial Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 5.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,426 shares of the medical equipment provider's stock after selling 5,983 shares during the quarter. Corebridge Financial Inc. owned about 0.16% of Lantheus worth $10,058,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC acquired a new position in Lantheus in the 4th quarter valued at about $27,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after buying an additional 280 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Lantheus by 118.0% during the 4th quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock valued at $91,000 after buying an additional 551 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the subject of several recent analyst reports. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Lantheus currently has an average rating of "Moderate Buy" and an average target price of $129.43.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock worth $6,110,806. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.5 %

NASDAQ LNTH traded up $1.44 during trading on Monday, hitting $97.60. The stock had a trading volume of 1,052,632 shares, compared to its average volume of 942,562. The company has a market capitalization of $6.68 billion, a PE ratio of 16.24 and a beta of 0.38. The firm has a 50 day moving average price of $93.34 and a 200 day moving average price of $96.34. Lantheus Holdings, Inc. has a twelve month low of $58.16 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.